Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food and Drug ...
Hims & Hers, one of the most popular telehealth services in the world, is in danger of losing one of its central revenue sources. The U.S. Food and Drug Administration (FDA) removed semaglutide ...
Stocks slid Friday as Wall Street’s mood darkened on the heels of soft economic data.The Dow Jones Industrial Average recorded its worst day of the year, closing down 1.7%, while the S&P 500 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results